Serina Therapeutics, a clinical-stage biotechnology company, has announced a major development in the treatment of Tardive Dyskinesia (TD) by advancing its innovative POZ-VMAT2i candidate into clinical development. This move, reported…
Here's a more detailed explanation. The newest American Cancer Society study just released suggests that a diagnosis of cancer is no longer a death sentence. According to a recent U.S.…
Acknowledgement: This article was shared with Patient Worthy by our friends at Stork Genetics. To see the original article, please click here. For more information about women affected by X-linked…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
